- Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.
- Apabetalone is a therapeutic candidate which is a protein inhibitor that works in preventing and treating illness progression
- This drug candidate has the potential to act against COVID-19 with a dual-mechanism
- The treatment could potentially reduce the severity and duration of PCC and other illnesses
- The company is finalizing the phase three study protocol of apabetalone in PCC
- Resverlogix Corp. (RVX) is up 2.56 per cent and is trading at $0.20 per share as of 2:00 p.m. ET
Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.
Apabetalone is a therapeutic candidate, a protein inhibitor that works to prevent and treat illness progression by regulating the expression of disease-causing genes.
Dr. Michael Sweeney, Senior Vice President of Clinical Development at Resverlogix, commented,
“There are currently few available treatment options for this group of people, and we feel that apabetalone has great potential to help them… individuals who contract COVID-19 are at greater risk of negative cardiovascular outcomes, and we have seen the cardioprotective benefit of apabetalone in other high-risk populations.”
The company stated this drug candidate has the potential to act against COVID-19 with a unique dual-mechanism first by preventing viruses from entering the cells and replicating and by avoiding excessive inflammatory reactions that can cause severe and lasting organ damage.
The treatment could potentially reduce the severity and duration of PCC and may be able to address several variants and other diseases.
The company is finalizing the phase three study protocol of apabetalone in PCC. It plans to launch the trial during the first half of 2023, subject to all necessary approvals and securing the necessary resources.
Resverlogix Corp. (RVX) is up 2.56 per cent and is trading at $0.20 per share as of 2:00 p.m. ET.
